Orchard Therapeutics announced a strategic collaboration to research, develop, manufacture and commercialize OTL-105, a newly disclosed investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema, a life-threatening rare disorder that causes recurring swelling attacks in the face, throat, extremities and abdomen.
July 1, 2021
· 13 min read